Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNPRESCRIB-D
2026-526314-90-00Phase 4Authorised
- Sponsor
- Capital Region of Denmark
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of femicept, sertraline, duloxetine and Placebo-COD Research Private Ltd in major depressive disorder (MDD) (2 arms), sponsored by Capital Region of Denmark. Primary endpoints: Mean Hamilton Depressive Rating Scale 6-item score and Mean total Verbal Affective Memory Task 24 recall score. Planned start Jun 2026; status: authorised.
02
Drugs
femiceptsertralineduloxetinePlacebo-COD Research Private Ltd
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2026-526314-90-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526314-90-00.